Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury

Summary

Phase 3 multicenter study to be conducted in up to 90 qualified participating sites globally to assess the efficacy and safety of Reltecimod vs placebo in patients with sepsis-associated Stage 2/3 AKI.

Timeline

Start

2018-05-24

Primary completion

2019-12-14

Completion

2019-12-14

Outcome

Outcome not reported

Stopped (Enrollment): “Very slow enrollment of target patient population”

Drugs

Indications